|
GB1351025A
(en)
*
|
1971-08-20 |
1974-04-24 |
Aron Md Samuel J |
Oxadiazol-5-yl biguanide derivatives method for their preparation and pharmaceutical compositions containing them
|
|
ZA876930B
(en)
|
1986-10-07 |
1988-05-25 |
Hoffmann La Roche |
Pharmaceutical compositions
|
|
IT1245890B
(it)
|
1991-04-12 |
1994-10-25 |
Alfa Wassermann Spa |
Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
|
|
GB9203347D0
(en)
|
1992-02-17 |
1992-04-01 |
Wellcome Found |
Hypolipidaemic compounds
|
|
US5234697A
(en)
|
1992-06-22 |
1993-08-10 |
Digestive Care Inc. |
Compositions of gastric acid-resistant microspheres containing salts of bile acids
|
|
US5415872A
(en)
|
1992-06-22 |
1995-05-16 |
Digestive Care Inc. |
Compositions of gastric acid-resistant microspheres containing salts of bile acids
|
|
IL108634A0
(en)
|
1993-02-15 |
1994-05-30 |
Wellcome Found |
Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
|
|
IL108633A
(en)
|
1993-02-15 |
1998-07-15 |
Wellcome Found |
History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
|
|
KR970005178B1
(ko)
|
1993-12-28 |
1997-04-14 |
이승철 |
피로회복제 조성물
|
|
US5589358A
(en)
|
1993-12-29 |
1996-12-31 |
Univ Wake Forest |
Ileal bile acid transporter compositions and methods
|
|
ZA956647B
(en)
|
1994-08-10 |
1997-02-10 |
Wellcome Found |
Hypolipidaemic compounds.
|
|
US6107494A
(en)
|
1994-09-13 |
2000-08-22 |
G.D. Searle And Company |
Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US5994391A
(en)
*
|
1994-09-13 |
1999-11-30 |
G.D. Searle And Company |
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
|
GB9423172D0
(en)
|
1994-11-17 |
1995-01-04 |
Wellcom Foundation The Limited |
Hypolipidemic benzothiazepines
|
|
US6861053B1
(en)
|
1999-08-11 |
2005-03-01 |
Cedars-Sinai Medical Center |
Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
|
|
NZ331813A
(en)
|
1996-03-11 |
2001-03-30 |
G |
Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
DE122010000020I1
(de)
|
1996-04-25 |
2010-07-08 |
Prosidion Ltd |
Verfahren zur Senkung des Blutglukosespiegels in Säugern
|
|
US5908830A
(en)
|
1996-10-31 |
1999-06-01 |
Merck & Co., Inc. |
Combination therapy for the treatment of diabetes and obesity
|
|
GB9704208D0
(en)
*
|
1997-02-28 |
1997-04-16 |
Glaxo Group Ltd |
Chemical compounds
|
|
DK0864582T3
(da)
|
1997-03-14 |
2003-09-29 |
Aventis Pharma Gmbh |
Hypolidemiske 1,4-benzothiazepin-1,1-dioxider
|
|
US5900233A
(en)
|
1997-10-16 |
1999-05-04 |
Day; Charles E. |
Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome
|
|
KR20010015884A
(ko)
|
1997-12-19 |
2001-02-26 |
윌리암스 로저 에이 |
거울상이성질체적으로 풍부한 테트라히드로벤조티에핀옥시드의 제조방법
|
|
GB9800428D0
(en)
|
1998-01-10 |
1998-03-04 |
Glaxo Group Ltd |
Chemical compounds
|
|
EP2823812A1
(en)
|
1998-02-02 |
2015-01-14 |
Trustees Of Tufts College |
Dipeptidylpeptidase IV inhibitors for use in the treatment of Type II diabetes
|
|
JP2000026300A
(ja)
|
1998-07-02 |
2000-01-25 |
Pola Chem Ind Inc |
血管内皮細胞保護医薬組成物
|
|
EP1342475A1
(en)
|
1998-12-23 |
2003-09-10 |
G.D. Searle LLC. |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
|
SE9901387D0
(sv)
|
1999-04-19 |
1999-04-19 |
Astra Ab |
New pharmaceutical foromaulations
|
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
|
CZ290178B6
(cs)
|
1999-07-22 |
2002-06-12 |
Sankyo Company Limited |
Deriváty cyklobutenu
|
|
DK1248604T4
(da)
|
2000-01-21 |
2012-05-21 |
Novartis Ag |
Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
|
|
SE0000772D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2001077325A1
(fr)
|
2000-04-12 |
2001-10-18 |
Takeda Chemical Industries, Ltd. |
Nouvelle proteine de recepteur couple aux proteines g et adn de celle-ci
|
|
US20020183307A1
(en)
*
|
2000-07-26 |
2002-12-05 |
Tremont Samuel J. |
Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
|
|
CN100423715C
(zh)
|
2000-07-28 |
2008-10-08 |
霍夫曼-拉罗奇有限公司 |
新型药物组合物
|
|
CN1466465A
(zh)
*
|
2000-08-01 |
2004-01-07 |
��Ұ����ҩ��ʽ���� |
肥胖或脂肪肝的预防或治疗药物
|
|
JP4003069B2
(ja)
|
2000-11-17 |
2007-11-07 |
萬有製薬株式会社 |
新規なグアノシン三リン酸（ｇｔｐ）結合タンパク質共役型のレセプタータンパク質、ｂｇ３７
|
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2002053548A1
(fr)
*
|
2000-12-27 |
2002-07-11 |
Banyu Pharmaceutical Co.,Ltd. |
Derives de la benzothiazepine
|
|
WO2002078625A2
(en)
|
2001-03-28 |
2002-10-10 |
Pharmacia Corporation |
Therapeutic combinations for cardiovascular and inflammatory indications
|
|
ATE363917T1
(de)
|
2001-07-19 |
2007-06-15 |
Pharmacia Corp |
Kombination von einem aldosterone rezeptor antagonisten und einem hmg coa reduktase hemmer
|
|
BR0212031A
(pt)
|
2001-08-22 |
2004-08-03 |
Aventis Pharma Gmbh |
Preparados de combinação de derivados de 1,1-dióxido de 1-4-benzotiepina com outras substâncias ativas e seu emprego
|
|
GB0121337D0
(en)
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121621D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121622D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
PL216023B1
(pl)
|
2001-09-08 |
2014-02-28 |
Astrazeneca Ab |
Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny
|
|
CA2462455C
(en)
|
2001-10-01 |
2012-07-17 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Development of a preventive vaccine for filovirus infection in primates
|
|
US6740663B2
(en)
|
2001-11-02 |
2004-05-25 |
G.D. Searle, Llc |
Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
|
|
GB0229931D0
(en)
*
|
2002-12-21 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
|
AU2003207431A1
(en)
|
2002-01-17 |
2003-09-02 |
Pharmacia Corporation |
Novel alkyl/aryl hydroxy or keto thiepines.
|
|
GB0201850D0
(en)
|
2002-01-26 |
2002-03-13 |
Astrazeneca Ab |
Therapeutic treatment
|
|
US20040014806A1
(en)
|
2002-03-08 |
2004-01-22 |
Pharmacia Corporation |
Methods and compositions for lowering levels of blood lipids
|
|
GB0209467D0
(en)
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2003099264A1
(en)
|
2002-05-23 |
2003-12-04 |
Umd, Inc. |
Compositions and method for transmucosal drug delivery and cryoprotection
|
|
CN100494185C
(zh)
*
|
2002-08-28 |
2009-06-03 |
旭化成制药株式会社 |
新型季铵化合物
|
|
US7312208B2
(en)
*
|
2002-08-28 |
2007-12-25 |
Asahi Kasei Pharma Corporation |
Quaternary ammonium compounds
|
|
US20040122033A1
(en)
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
|
US20040138145A1
(en)
|
2002-12-12 |
2004-07-15 |
Aventis Pharma S.A. |
Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
|
|
GB0304194D0
(en)
|
2003-02-25 |
2003-03-26 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
|
EP1635832A2
(en)
*
|
2003-06-06 |
2006-03-22 |
Merck & Co., Inc. |
Combination therapy for the treatment of diabetes
|
|
JP2005097216A
(ja)
|
2003-09-26 |
2005-04-14 |
Kaneka Corp |
ＰＰＡＲγリガンド剤
|
|
KR20070026392A
(ko)
|
2004-02-27 |
2007-03-08 |
아사히 가세이 파마 가부시키가이샤 |
신규 벤조티아제핀 및 벤조티에핀 화합물
|
|
EP1799263A4
(en)
|
2004-09-15 |
2009-07-29 |
Harvard College |
REDUCTION OF ER-STRESS IN THE TREATMENT OF ADIPOSITAS AND DIABETES
|
|
EP1810689A4
(en)
*
|
2004-10-15 |
2009-07-22 |
Mitsubishi Tanabe Pharma Corp |
MEANS FOR THE PREVENTION AND / OR TREATMENT OF DIABETES
|
|
EP1807066A1
(en)
|
2004-10-25 |
2007-07-18 |
Novartis AG |
Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
|
|
JP2008521800A
(ja)
|
2004-11-24 |
2008-06-26 |
セオ ホン ユー |
水可溶化胆汁酸投薬処方の乾燥形態、その製造方法及び用途
|
|
WO2006086727A2
(en)
*
|
2005-02-09 |
2006-08-17 |
Entelos, Inc. |
Treating diabetes with glucagon-like peptide-1 secretagogues
|
|
US20060193895A1
(en)
|
2005-02-25 |
2006-08-31 |
Use-Techno Corporation |
Additive for food and beverage, pharmaceutical composition, GLUT4 translocator, and method for translocating GLUT4
|
|
FR2883284A1
(fr)
|
2005-03-15 |
2006-09-22 |
Commissariat Energie Atomique |
Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
|
|
US20060222709A1
(en)
*
|
2005-03-18 |
2006-10-05 |
Agi Therapeutics Research Ltd. |
Metformin methods and formulations for treating chronic constipation
|
|
PE20061245A1
(es)
*
|
2005-03-30 |
2007-01-06 |
Generex Pharm Inc |
Composiciones para la transmision transmucosa oral de la metformina
|
|
US20080031968A1
(en)
|
2005-04-01 |
2008-02-07 |
The Brigham And Women's Hospital, Inc. |
Methods for increasing cellular energy expenditure
|
|
WO2006105913A1
(en)
|
2005-04-04 |
2006-10-12 |
Julius-Maximillians-Universität Würzburg |
Tripeptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1
|
|
US8207133B1
(en)
|
2005-04-04 |
2012-06-26 |
Julius-Maximilians-Universitat Wurzburg |
Peptides that down regulate the activity of plasma membrane transporters including sodium-D-glucose cotransporter SGLT1
|
|
WO2006116814A1
(en)
|
2005-05-02 |
2006-11-09 |
Vanadis Bioscience Ltd |
Composition and uses thereof
|
|
US20070025953A1
(en)
|
2005-07-27 |
2007-02-01 |
Jones Michael R |
Co-therapy for diabetic conditions
|
|
RU2008116578A
(ru)
|
2005-09-30 |
2009-11-10 |
Новартис АГ (CH) |
Применение ингибиторов dpp-iv для лечения аутоиммунных заболеваний и отторжения трансплантата
|
|
WO2007076260A2
(en)
|
2005-12-19 |
2007-07-05 |
Smithkline Beecham Corporation |
Farnesoid x receptor agonists
|
|
EA200801551A1
(ru)
|
2006-01-20 |
2009-02-27 |
Смитклайн Бичем Корпорейшн |
Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
|
|
WO2007095174A2
(en)
|
2006-02-14 |
2007-08-23 |
Intercept Pharmaceuticals, Inc. |
Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
|
|
CN101522703B
(zh)
|
2006-06-27 |
2013-04-17 |
英特塞普特医药品公司 |
胆酸派生物及其在制备预防或治疗fxr介导的疾病或状况的药物中的应用
|
|
US20080065136A1
(en)
|
2006-08-30 |
2008-03-13 |
Andrew Young |
Distender device and method for treatment of obesity and metabolic and other diseases
|
|
CL2007003035A1
(es)
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
|
DE102006053635B4
(de)
|
2006-11-14 |
2011-06-30 |
Sanofi-Aventis Deutschland GmbH, 65929 |
Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
|
WO2008058631A1
(de)
*
|
2006-11-14 |
2008-05-22 |
Sanofi-Aventis Deutschland Gmbh |
Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US20090035306A1
(en)
|
2006-11-29 |
2009-02-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
|
JP5292310B2
(ja)
|
2007-01-19 |
2013-09-18 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
Ｔｇｒ５調節剤としての２３−置換胆汁酸およびその使用方法
|
|
WO2008097976A1
(en)
|
2007-02-09 |
2008-08-14 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
WO2009026537A1
(en)
|
2007-08-23 |
2009-02-26 |
Theracos, Inc. |
Benzylbenzene derivatives and methods of use
|
|
ES2663948T3
(es)
|
2008-11-19 |
2018-04-17 |
Intercept Pharmaceuticals, Inc. |
Moduladores de TGR5 y método de uso de los mismos
|
|
JP2012509892A
(ja)
|
2008-11-26 |
2012-04-26 |
サティオゲン ファーマシューティカルズ，インク． |
サティオゲン類を含有する組成物及び使用の方法
|
|
EP2367554A4
(en)
|
2008-11-26 |
2020-03-25 |
Satiogen Pharmaceuticals, Inc. |
Bile acid reflux inhibitor for the treatment of obesity and diabetes
|
|
US20110065676A1
(en)
|
2009-06-24 |
2011-03-17 |
Schering Corporation |
Combination therapies comprising par1 antagonists with nar agonists
|
|
EP3593802A3
(en)
|
2010-05-26 |
2020-03-25 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
|
ES2586931T3
(es)
|
2010-11-04 |
2016-10-19 |
Albireo Ab |
Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
|
|
RU2619215C2
(ru)
|
2010-11-08 |
2017-05-12 |
Альбирео Аб |
Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты
|
|
EP2637667A4
(en)
|
2010-11-08 |
2014-06-25 |
Albireo Ab |
IBAT HEMMER FOR THE TREATMENT OF METABOLISM DISEASES AND RELATED ACCIDENTS
|